378 related articles for article (PubMed ID: 33410258)
1. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.
Berliner JL; Cummings SA; Boldt Burnett B; Ricker CN
J Genet Couns; 2021 Apr; 30(2):342-360. PubMed ID: 33410258
[TBL] [Abstract][Full Text] [Related]
2. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors.
Berliner JL; Fay AM;
J Genet Couns; 2007 Jun; 16(3):241-60. PubMed ID: 17508274
[TBL] [Abstract][Full Text] [Related]
3. A survey of genetic counselors about the needs of 18-25 year olds from families with hereditary breast and ovarian cancer syndrome.
Werner-Lin A; Ratner R; Hoskins LM; Lieber C
J Genet Couns; 2015 Feb; 24(1):78-87. PubMed ID: 25011978
[TBL] [Abstract][Full Text] [Related]
4. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
[TBL] [Abstract][Full Text] [Related]
5. Genetic counselors' perspectives on population-based screening for BRCA-related hereditary breast and ovarian cancer and Lynch syndrome.
De Simone LM; Arjunan A; Vogel Postula KJ; Maga T; Bucheit LA
J Genet Couns; 2021 Feb; 30(1):158-169. PubMed ID: 32562467
[TBL] [Abstract][Full Text] [Related]
6. [Genetic Counseling of HBOC and Japanese Organization of HBOC].
Fukushima Y
Gan To Kagaku Ryoho; 2017 Feb; 44(2):107-110. PubMed ID: 28223668
[TBL] [Abstract][Full Text] [Related]
7. Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian.
Hessock M; Brewer T; Hutson S; Anderson J
Nurs Womens Health; 2021 Jun; 25(3):187-197. PubMed ID: 33933425
[TBL] [Abstract][Full Text] [Related]
8. Prenatal genetic counseling practices regarding recommendations for cancer genetic counseling: A retrospective chart review from two academic institutions.
Saba LF; Sullivan CM; Solomon T; Huguenard S; Nassef SA
J Genet Couns; 2022 Oct; 31(5):1062-1070. PubMed ID: 35434961
[TBL] [Abstract][Full Text] [Related]
9. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer.
Berliner JL; Fay AM; Cummings SA; Burnett B; Tillmanns T
J Genet Couns; 2013 Apr; 22(2):155-63. PubMed ID: 23188549
[TBL] [Abstract][Full Text] [Related]
10. Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer.
Szender JB; Kaur J; Clayback K; Hutton ML; Mikkelson J; Odunsi K; Dresbold C
Int J Gynecol Cancer; 2018 Jan; 28(1):26-33. PubMed ID: 28930807
[TBL] [Abstract][Full Text] [Related]
11. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
12. Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
Bellcross CA
Obstet Gynecol Clin North Am; 2022 Mar; 49(1):117-147. PubMed ID: 35168766
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system.
Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
Clin Genet; 2022 Mar; 101(3):324-334. PubMed ID: 34927729
[TBL] [Abstract][Full Text] [Related]
14. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
15. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
16. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
[TBL] [Abstract][Full Text] [Related]
17. Cancer Genetic Counseling and Testing in an Era of Rapid Change.
Hooker GW; Clemens KR; Quillin J; Vogel Postula KJ; Summerour P; Nagy R; Buchanan AH
J Genet Couns; 2017 Dec; 26(6):1244-1253. PubMed ID: 28434142
[TBL] [Abstract][Full Text] [Related]
18. Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.
Malhotra H; Kowtal P; Mehra N; Pramank R; Sarin R; Rajkumar T; Gupta S; Bapna A; Bhattacharyya GS; Gupta S; Maheshwari A; Mannan AU; Reddy Kundur R; Sekhon R; Singhal M; Smruti BK; Sp S; Suryavanshi M; Verma A
JCO Glob Oncol; 2020 Jul; 6():991-1008. PubMed ID: 32628584
[TBL] [Abstract][Full Text] [Related]
19. Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.
Kotnik U; Peterlin B; Lovrecic L
BMC Cancer; 2021 Jun; 21(1):665. PubMed ID: 34082720
[TBL] [Abstract][Full Text] [Related]
20. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
